Abstract
AbstractAnti-neoplastic drugs have made major advancements in oncology, however they are not without cardiovascular consequences. We present a patient with cutaneous T-cell lymphoma receiving Targretin therapy who presented with accelerated atherosclerosis. His triglyceride level (TG) was greater than 1000 mg/dL, which rapidly improved with discontinuation of Targretin.
Publisher
Springer Science and Business Media LLC
Subject
Materials Science (miscellaneous)
Reference9 articles.
1. Targretin [package insert], Bridgewater (NJ): Valeant Pharmaceuticals North America LLC; 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021055s010lbl.pdf.
2. Scaribrick JJ, Morris S, Azurdia R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol. 2013;168(1):192–200.
3. Cabello I, Pintó X, Alia P, et al. Association of APOA5 and APOC3 genetic polymorphisms with severity of hypertriglyceridemia in patients with cutaneous T-cell lymphoma treated with Bexarotene. JAMA Dermatol. 2018;154(12):1424–31.
4. Maminakis C, Whitman AC, Islam N. Bexarotene-induced hypertriglyceridemia: a case report. Case Rep Oncol. 2018;11:234–8.
5. Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non–ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835–42. https://doi.org/10.1001/jama.284.7.835.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Bexarotene;Reactions Weekly;2021-04